Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

An outcome-driven threshold for pulse pressure amplification

QF. Huang, DW. An, LS. Aparicio, YB. Cheng, FF. Wei, YL. Yu, CS. Sheng, WY. Yang, TJ. Niiranen, J. Boggia, K. Stolarz-Skrzypek, V. Tikhonoff, N. Gilis-Malinowska, W. Wojciechowska, E. Casiglia, K. Narkiewicz, J. Filipovský, K. Kawecka-Jaszcz, TS....

. 2024 ; 47 (9) : 2478-2488. [pub] 20240722

Language English Country England, Great Britain

Document type Journal Article, Meta-Analysis

Persistent link   https://www.medvik.cz/link/bmc24019088
E-resources Online Full text

NLK ProQuest Central from 2015-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2015-01-01 to 1 year ago

Links

PubMed 39039284
DOI 10.1038/s41440-024-01779-4
Knihovny.cz E-resources

Pulse pressure amplification (PPA) is the brachial-to-aortic pulse pressure ratio and decreases with age and cardiovascular risk factors. This individual-participant meta-analysis of population studies aimed to define an outcome-driven threshold for PPA. Incidence rates and standardized multivariable-adjusted hazard ratios (HRs) of cardiovascular and coronary endpoints associated with PPA, as assessed by the SphygmoCor software, were evaluated in the International Database of Central Arterial Properties for Risk Stratification (n = 5608). Model refinement was assessed by the integrated discrimination (IDI) and net reclassification (NRI) improvement. Age ranged from 30 to 96 years (median 53.6). Over 4.1 years (median), 255 and 109 participants experienced a cardiovascular or coronary endpoint. In a randomly defined discovery subset of 3945 individuals, the rounded risk-carrying PPA thresholds converged at 1.3. The HRs for cardiovascular and coronary endpoints contrasting PPA < 1.3 vs ≥1.3 were 1.54 (95% confidence interval [CI]: 1.00-2.36) and 2.45 (CI: 1.20-5.01), respectively. Models were well calibrated, findings were replicated in the remaining 1663 individuals analyzed as test dataset, and NRI was significant for both endpoints. The HRs associating cardiovascular and coronary endpoints per PPA threshold in individuals <60 vs ≥60 years were 3.86 vs 1.19 and 6.21 vs 1.77, respectively. The proportion of high-risk women (PPA < 1.3) was higher at younger age (<60 vs ≥60 years: 67.7% vs 61.5%; P < 0.001). In conclusion, over and beyond common risk factors, a brachial-to-central PP ratio of <1.3 is a forerunner of cardiovascular coronary complications and is an underestimated risk factor in women aged 30-60 years. Our study supports pulse wave analysis for risk stratification.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019088
003      
CZ-PrNML
005      
20241024111618.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41440-024-01779-4 $2 doi
035    __
$a (PubMed)39039284
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Huang, Qi-Fang $u Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
245    13
$a An outcome-driven threshold for pulse pressure amplification / $c QF. Huang, DW. An, LS. Aparicio, YB. Cheng, FF. Wei, YL. Yu, CS. Sheng, WY. Yang, TJ. Niiranen, J. Boggia, K. Stolarz-Skrzypek, V. Tikhonoff, N. Gilis-Malinowska, W. Wojciechowska, E. Casiglia, K. Narkiewicz, J. Filipovský, K. Kawecka-Jaszcz, TS. Nawrot, JG. Wang, Y. Li, JA. Staessen, International Database of Central Arterial Properties for Risk Stratification (IDCARS) Investigators
520    9_
$a Pulse pressure amplification (PPA) is the brachial-to-aortic pulse pressure ratio and decreases with age and cardiovascular risk factors. This individual-participant meta-analysis of population studies aimed to define an outcome-driven threshold for PPA. Incidence rates and standardized multivariable-adjusted hazard ratios (HRs) of cardiovascular and coronary endpoints associated with PPA, as assessed by the SphygmoCor software, were evaluated in the International Database of Central Arterial Properties for Risk Stratification (n = 5608). Model refinement was assessed by the integrated discrimination (IDI) and net reclassification (NRI) improvement. Age ranged from 30 to 96 years (median 53.6). Over 4.1 years (median), 255 and 109 participants experienced a cardiovascular or coronary endpoint. In a randomly defined discovery subset of 3945 individuals, the rounded risk-carrying PPA thresholds converged at 1.3. The HRs for cardiovascular and coronary endpoints contrasting PPA < 1.3 vs ≥1.3 were 1.54 (95% confidence interval [CI]: 1.00-2.36) and 2.45 (CI: 1.20-5.01), respectively. Models were well calibrated, findings were replicated in the remaining 1663 individuals analyzed as test dataset, and NRI was significant for both endpoints. The HRs associating cardiovascular and coronary endpoints per PPA threshold in individuals <60 vs ≥60 years were 3.86 vs 1.19 and 6.21 vs 1.77, respectively. The proportion of high-risk women (PPA < 1.3) was higher at younger age (<60 vs ≥60 years: 67.7% vs 61.5%; P < 0.001). In conclusion, over and beyond common risk factors, a brachial-to-central PP ratio of <1.3 is a forerunner of cardiovascular coronary complications and is an underestimated risk factor in women aged 30-60 years. Our study supports pulse wave analysis for risk stratification.
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    12
$a krevní tlak $x fyziologie $7 D001794
650    _2
$a mužské pohlaví $7 D008297
650    12
$a kardiovaskulární nemoci $x patofyziologie $7 D002318
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a rizikové faktory $7 D012307
650    _2
$a rizikové faktory kardiovaskulárních chorob $7 D000082742
650    _2
$a analýza pulzové vlny $7 D063177
650    _2
$a arteria brachialis $x fyziologie $7 D001916
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
700    1_
$a An, De-Wei $u Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China $u Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium $u Research Unit Environment and Health, Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium
700    1_
$a Aparicio, Lucas S $u Servicio de Clínica Médica, Sección Hipertensión Arterial, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
700    1_
$a Cheng, Yi-Bang $u Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
700    1_
$a Wei, Fang-Fei $u Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium $u Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
700    1_
$a Yu, Yu-Ling $u Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium $u Research Unit Environment and Health, Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium
700    1_
$a Sheng, Chang-Sheng $u Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
700    1_
$a Yang, Wen-Yi $u Department of Cardiology, Shanghai General Hospital, Shanghai, China
700    1_
$a Niiranen, Teemu J $u Department of Chronic Disease Prevention, Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland
700    1_
$a Boggia, José $u Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay
700    1_
$a Stolarz-Skrzypek, Katarzyna $u First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland
700    1_
$a Tikhonoff, Valérie $u Department of Medicine, University of Padua, Padua, Italy
700    1_
$a Gilis-Malinowska, Natasza $u Hypertension Unit, Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland
700    1_
$a Wojciechowska, Wiktoria $u First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland
700    1_
$a Casiglia, Edoardo $u Department of Medicine, University of Padua, Padua, Italy
700    1_
$a Narkiewicz, Krzysztof $u Hypertension Unit, Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland
700    1_
$a Filipovský, Jan $u Faculty of Medicine, Charles University, Pilsen, Czech Republic
700    1_
$a Kawecka-Jaszcz, Kalina $u First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland
700    1_
$a Nawrot, Tim S $u Research Unit Environment and Health, Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium
700    1_
$a Wang, Ji-Guang $u Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
700    1_
$a Li, Yan $u Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. liyanshcn@163.com
700    1_
$a Staessen, Jan A $u Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. jan.staessen@appremed.org $u Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium. jan.staessen@appremed.org $u Biomedical Sciences Group, Faculty of Medicine, University of Leuven, Leuven, Belgium. jan.staessen@appremed.org
710    2_
$a International Database of Central Arterial Properties for Risk Stratification (IDCARS) Investigators
773    0_
$w MED00006041 $t Hypertension research : official journal of the Japanese Society of Hypertension $x 1348-4214 $g Roč. 47, č. 9 (2024), s. 2478-2488
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39039284 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111611 $b ABA008
999    __
$a ok $b bmc $g 2201733 $s 1231061
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 47 $c 9 $d 2478-2488 $e 20240722 $i 1348-4214 $m Hypertension research : official journal of the Japanese Society of Hypertension $n Hypertens Res $x MED00006041
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options